Both in Diagnostics
Myriad Genetics vs Celldex Therapeutics
Over the past year MYGN returned −27.0% and CLDX returned +20.1%; their daily moves had a correlation of 0.23.
MYGN −27.0% CLDX +20.1%Growth of $1, one year, split-adjusted
| Metric | MYGN | CLDX |
|---|---|---|
| Price | $5.97 | $29.73 |
| Market cap | $571.0M | $2.33B |
| Today | −1.16% | +0.05% |
| 1 month | +39.5% | −4.1% |
| 6 months | +45.3% | −13.6% |
| Year to date | −2.9% | +9.4% |
| 1 year | −27.0% | +20.1% |
| Revenue growth (YoY) | −10.5% | −97.0% |
| Gross margin | 66.6% | 100.0% |
| Net margin | −22.7% | −334104.5% |
| P/E (TTM) | — | — |
| Price / sales | 0.7× | 14,774.0× |
| Net cash | -$5.5M | $717.6M |
| Dividend yield | — | — |
| Volatility (60d) | 85.1% | 47.6% |
| Short % of float | 10.1% | 13.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).